Cerebral angiography with non-ionic (metrizamide) and ionic (meglumine metrizoate) watersoluble contrast media. A comparative study with double blind technic.
The adverse effects of cerebral angiography with metrizamide and meglumine metrizoate were compared in 20 patients for each contrast medium using a double blind technic. Deterioration of the EEG and bradycardial reactions were seen more often with meglumine metrizoate than with metrizamide and these differences were statistically significant. Metrizamide also had a shorter circulation time, less influence on the blood pressure and EMG than meglumine metrizoate, but these differences were not statistically significant. The clinical examinations showed no difference in the minor adverse effects. One patient had transient hemiparesis and dysarthria after angiography with meglumine metrizoate but no serious complications were seen in the others.
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001919:Bradycardia / Q000139:chemically induced; D002533:Cerebral Angiography / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects*; D004569:Electroencephalography; D005260:Female; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006429:Hemiplegia / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D008297:Male; D008793:Metrizamide / Q000009:adverse effects*; D008794:Metrizoic Acid / Q000009:adverse effects*; D008875:Middle Aged; D009132:Muscles / Q000187:drug effects; D013064:Speech Disorders / Q000139:chemically induced
D003287:Contrast Media; D007463:Iodobenzoates; D008794:Metrizoic Acid; D008793:Metrizamide